Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2119 studies found for:    breast,cancer,treatment | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
Condition: Vaginal Atrophy
Interventions: Drug: estriol;   Drug: Placebo
2 Recruiting Hula, a Physical Activity Intervention for Female-Cancer Survivors
Conditions: Physical Activity;   Breast Cancer;   Cervical Cancer;   Ovarian Cancer;   Endometrial Cancer
Intervention: Behavioral: Hula
3 Not yet recruiting Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
Conditions: Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer
Interventions: Radiation: Electron Beam Therapy;   Procedure: Lumpectomy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Procedure: Reconstructive Surgery
4 Not yet recruiting A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older
Conditions: Breast Cancer;   Estrogen Receptor Positive Breast Cancer;   Node-negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: Other: Breast Cancer Treatment Decision Aid for women 70+;   Other: Usual Care
5 Recruiting Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes
Condition: Breast Cancer
Intervention: Radiation: Adjuvant Hypofractionated Radiation
6 Recruiting Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Condition: HR+ HER2- Postmenopausal Advanced Breast Cancer
Interventions: Drug: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant;   Drug: Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
7 Recruiting PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
Condition: Breast Cancer
Interventions: Drug: Neoadjuvant tamoxifen + goserelin (premenopausal women);   Drug: Neoadjuvant letrozole (postmenopausal women);   Drug: Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone);   Drug: Neoadjuvant docetaxel + cyclophosphamide;   Drug: Neoadjuvant docetaxel;   Drug: Neoadjuvant docetaxel + trastuzumab + pertuzumab;   Drug: Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab;   Drug: Neoadjuvant olaparib;   Drug: Neoadjuvant olaparib + carboplatin (if lack of response to olaparib alone);   Procedure: Breast conserving surgery or mastectomy + SNB/axillary dissection;   Radiation: Postoperative radiotherapy breast/chest wall + regional lymph nodes;   Drug: Adjuvant trastuzumab;   Drug: Adjuvant letrozole (postmenopausal women);   Drug: Adjuvant tamoxifen + goserelin (premenopausal women);   Drug: Adjuvant palbociclib (if palbociclib given neoadjuvant);   Drug: Adjuvant Epirubicin+ Cyclophosphamide
8 Recruiting POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer
Condition: Breast Cancer
Interventions: Other: Adjuvant therapy;   Procedure: Axillary treatment
9 Not yet recruiting Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: Breast-Conserving Therapy;   Procedure: Mastectomy;   Drug: Adjuvant Chemotherapy;   Radiation: Radiation Therapy
10 Recruiting Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
Conditions: Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
11 Not yet recruiting EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer
Condition: Early Stage Breast Carcinoma
Intervention: Radiation: Omission of radiation therapy
12 Recruiting Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Ductal Breast Carcinoma With Predominant Intraductal Component;   Lobular Breast Carcinoma in Situ;   Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Tubular Ductal Breast Carcinoma
Interventions: Radiation: accelerated partial breast irradiation;   Radiation: intensity-modulated radiation therapy;   Radiation: image-guided radiation therapy;   Procedure: therapeutic conventional surgery;   Other: questionnaire administration;   Other: laboratory biomarker analysis
13 Recruiting Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: palliative surgery;   Procedure: therapeutic conventional surgery;   Radiation: palliative radiation therapy;   Radiation: radiation therapy
14 Recruiting Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
Condition: Breast Cancer
Interventions: Drug: Letrozole;   Drug: Tamoxifen;   Drug: Palbociclib;   Drug: Endocrine Therapy
15 Not yet recruiting Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Conditions: Breast Cancer;   Cancer of Breast;   Breast Neoplasms;   Cancer of the Breast
Interventions: Device: Oncotype DX® Breast Cancer Assay;   Behavioral: FACT-B;   Drug: Goserelin;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant;   Drug: Tamoxifen
16 Recruiting A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)
Condition: Breast Cancer
Interventions: Drug: Capecitabine;   Procedure: endocrine therapy
17 Recruiting Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment
18 Recruiting MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
Condition: Ductal Breast Carcinoma In Situ
Interventions: Procedure: Magnetic Resonance Imaging;   Procedure: Therapeutic Conventional Surgery;   Procedure: Therapeutic Surgical Procedure;   Radiation: Radiation Therapy;   Drug: Endocrine Therapy;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Other: Cytology Specimen Collection Procedure
19 Recruiting Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
Conditions: Breast Cancer;   Node-positive Breast Cancer;   Breast Adenocarcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma In Situ
Interventions: Radiation: External Beam Radiation Therapy;   Other: Questionnaire Administration;   Other: Laboratory Biomarker Analysis
20 Recruiting Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
Conditions: Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Circulating Tumor Cells
Intervention: Drug: trastuzumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years